Remove Clinical Development Remove Events Remove Small Molecule
article thumbnail

The rising impact of biomarkers in early clinical development

Drug Target Review

Haemoglobin A1c (HbA1c) is a validated surrogate endpoint for the reduction of microvascular complications associated with diabetes mellitus; reduced HIV-RNA levels serve as an endpoint for HIV disease control; and a reduction in low-density lipoprotein (LDL) cholesterol is used as an endpoint indicating lower likelihood of cardiovascular events.

article thumbnail

Bleximenib Shows Promise with Venetoclax and Azacitidine in AML

The Pharma Data

This small molecule inhibits the interaction between menin and its binding partners, thereby affecting the expression of genes that promote leukemia progression. The most frequently reported all-grade treatment-emergent adverse events (TEAEs) included nausea (65%), thrombocytopenia (61%), neutropenia (59%), and anemia (49%).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Best-in-Class Solutions Accelerate Development of GLP-1 Therapeutics

PPD

When the study started, the industry already knew that semaglutide could reduce the risk of adverse cardiovascular events in overweight or obese patients with diabetes. Were applying that expertise and commitment to every aspect of developing and running successful GLP-1 studies.

article thumbnail

Sentiment & Themes Emerging From JPM 2024

LifeSciVC

The market for each target class likely asymptotes with the number of Pharma or large biotech who can clinically develop and commercialize such assets; thus, there is intense focus on the first handful of assets to market. Small molecule GLP1s?

article thumbnail

Sosei Heptares and Biohaven Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio

The Pharma Data

Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists. The lead candidate, HTL0022562, has advanced through preclinical development demonstrating promising and differentiated properties for further investigation in human trials. Vlad Coric , M.D.,

article thumbnail

Sosei Heptares’ COVID-19 Program Identifies Potent Broad Spectrum Anti-Viral Small Molecules for Further Development

The Pharma Data

The Company is also aiming to leverage the highly conserved structure of the SARS-CoV-2 M pro protease as a basis for the design of novel oral small molecules against predicted future variants of SARS-CoV-2 and other related human viruses. View original content: [link]. SOURCE Sosei Heptares. Source link.

article thumbnail

Deconstructing the Diligence Process: An Approach to Vetting New Product Theses

LifeSciVC

There is a continuum of evidence for a given target – at one end are novel targets with some evidence of importance in disease, and at the other end are “de-risked” targets where the biology is precedented with an approved product or late-stage clinical asset(s). and whether a molecule’s pharmacology can help to mitigate safety risk.